279255-90-2

Usage

Uses

Used in Pharmaceutical Industry:
1H-Indole-1-carboxylic acid, 5-(hydroxymethyl)-, 1,1-dimethylethyl ester is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be efficiently converted into the desired active pharmaceutical ingredients. Its reactivity and stability make it a valuable component in the production of drugs targeting a wide range of therapeutic areas.
Used in Agrochemical Industry:
In the agrochemical sector, 1H-Indole-1-carboxylic acid, 5-(hydroxymethyl)-, 1,1-dimethylethyl ester serves as an essential building block in the creation of agrochemicals, such as pesticides and plant growth regulators. Its chemical properties allow for the development of effective compounds that can protect crops and enhance agricultural productivity.
Used in Organic Synthesis:
1H-Indole-1-carboxylic acid, 5-(hydroxymethyl)-, 1,1-dimethylethyl ester is also utilized in organic synthesis as a versatile reagent or precursor for the preparation of a variety of organic compounds. Its functional groups enable multiple synthetic pathways, leading to the formation of complex molecules with potential applications in various fields.

Upstream product

• 272438-11-6 1-tert-butoxycarbonyl-5-methoxycarbonylindole 
• 33140-84-0 methyl 2-(1H-indol-5-yl)acetate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 279256-09-6 1-(tert-butyloxycarbonyl)indole-5-carboxaldehyde 
• 335649-83-7 5-(tert-Butyl-dimethyl-silanyloxymethyl)-indole-1-carboxylic acid tert-butyl ester 
• 15893-47-7 (R)-2-amino-4-methylpentanamide 

Downstream Products

• 279255-91-3 2(R)-[(N-tert-butoxy-carbonylindol-5-ylmethyl)-(4-methoxybenzenesulfonyl)amino]-3-methylbutyric acid benzyl ester 
• 279256-09-6 1-(tert-butyloxycarbonyl)indole-5-carboxaldehyde 
• 442685-53-2 t-butyl 5-(bromomethyl)-1H-indole-1-carboxylate 

Relevant academic research and scientific papers

Nickel-Catalyzed Cross-Coupling of Vinyl Dioxanones to Form Enantiomerically Enriched Cyclopropanes

Under the conditions of nickel(0) catalysis, enantiomerically enriched vinyl dioxanones engage boroxines or B2(pin)2 in stereospecific cross-coupling to form diverse tetrasubstituted cyclopropanes bearing all-carbon quaternary stereocenters. The collective data corroborate a mechanism involving nickel(0)-mediated benzylic oxidative addition with inversion of stereochemistry followed by reversible olefin insertion to form a (cyclopropylcarbinyl)nickel complex, which upon reductive elimination releases the cyclopropane.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Sulfonamide bicyclic compounds

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their uses in inhibiting β-amyloid peptide (β-AP) production.

SUBSTITUTED PYRIDINONES

Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

Sulfonamide hydroxamates

A compound of the Formula (I): wherein Z, R1, R, and Ar2are as defined in the specification. This invention also relates to sulfonamide compounds of the Formula (I) that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use, and methods for preparing the compounds.